BIO

$373.660.33%-1.255

Nachbörslich: 374.91+1.26 +0.34%

Bio Rad Laboratories Inc (BIO)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$374.91

Offen:

$380.05

24-Stunden-Volumen:

47,242

Relatives Volumen:

0.21

Marktkapitalisierung:

$9.99B

Einnahmen:

$2.59B

Nettoeinkommen (Verlust:

$168.80M

KGV:

61.51

EPS:

$6.07

Netto-Cashflow:

$357.20M

1W Leistung:

-2.98%

1M Leistung:

+1.22%

6M Leistung:

+44.91%

1Y Leistung:

+20.16%

1-Tages-Spanne:

$371.54$380.92

1-Wochen-Bereich:

$361.27$390.16

52-Wochen-Spanne:

$236.73$396.23

Bio Rad Laboratories Inc Aktie (BIO) Unternehmensprofil

Firmenname

Bio Rad Laboratories Inc

Sektor

Healthcare

Branche

Medical Devices

Telefon

(510) 724-7000

Adresse

1000 ALFRED NOBEL DRIVE, HERCULES, USA

Mitarbeiter

7,450

@BioRadLifeSci

Nächster Verdiensttermin

2026-11-04

Neueste SEC-Einreichungen

SEC

BIO-Diskussionen auf X

Marktkapitalisierung

Umsatz

Nettogewinn

Free Cashflow

ENV

Bio Rad Laboratories Inc Aktie (BIO) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-05-15	Resumed	RBC Capital Mkts	Outperform
2026-04-07	Herabstufung	Citigroup	Buy → Neutral
2024-10-01	Hochstufung	Citigroup	Neutral → Buy
2024-08-28	Eingeleitet	Wells Fargo	Equal Weight
2024-06-03	Resumed	Jefferies	Hold
2024-04-03	Herabstufung	Citigroup	Buy → Neutral
2023-12-07	Eingeleitet	UBS	Buy
2023-06-16	Eingeleitet	Wells Fargo	Overweight
2022-12-07	Eingeleitet	RBC Capital Mkts	Outperform
2022-08-25	Eingeleitet	Credit Suisse	Outperform
2022-01-28	Bestätigt	Citigroup	Buy
2020-01-08	Eingeleitet	Wells Fargo	Overweight
2020-01-07	Eingeleitet	Citigroup	Buy
2018-10-17	Eingeleitet	Goldman	Buy
2018-09-20	Eingeleitet	Morgan Stanley	Equal-Weight
2018-02-16	Herabstufung	CL King	Buy → Neutral
2017-07-13	Eingeleitet	Wells Fargo	Outperform
2017-06-28	Hochstufung	Deutsche Bank	Hold → Buy
2017-01-18	Eingeleitet	Deutsche Bank	Hold
2016-10-13	Eingeleitet	CL King	Buy
2015-05-06	Bestätigt	Jefferies	Buy
2009-12-18	Eingeleitet	Maxim Group	Buy
2009-11-06	Eingeleitet	Jefferies & Co	Buy
2009-07-17	Eingeleitet	Soleil	Buy
2007-09-26	Eingeleitet	Banc of America Sec	Buy
2007-02-23	Herabstufung	Robert W. Baird	Outperform → Neutral

Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	2,583.20	2,566.50	2,671.30	2,802.20	2,922.50
Cost of revenue USD (M)	1,243.30	1,187.60	1,244.32	1,234.92	1,281.88
Gross profit USD (M)	1,339.90	1,378.90	1,426.95	1,567.33	1,640.66
Research and development USD (M)	275.60	295.90	247.43	256.89	271.66
Operating expenses USD (M)	-	-	1,089.15	1,084.71	1,151.23
Operating income USD (M)	47.20	269.00	337.80	482.62	489.43
Income before tax USD (M)	995.50	-2,342.50	-850.10	-4,704.27	5,438.15
Income tax expense USD (M)	235.60	-498.30	-212.78	-1,076.74	1,192.25
Net income USD (M)	759.90	-1,844.20	-637.32	-3,627.54	4,245.90
Basic EPS USD/shares	27.87	-65.36	-21.82	-121.79	142.33
Diluted EPS USD/shares	27.85	-	-21.82	-121.79	140.56
Basic weighted shares shares (M)	27.26	28.21	29.21	29.79	29.83
Diluted weighted shares shares (M)	27.28	28.21	29.21	29.79	30.21
Selling, general and administrative USD (M)	844.30	814.00	841.72	827.83	879.57

Bio Rad Laboratories Inc-Aktie (BIO) Insiderhandel

DiVincenzo Jonathan P.Oct 24 '26
President & COO
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
1,869
Wert ($)
0
#Aktien Gesamt
3,832
EVRAN SEDATOct 20 '26
EVP, Global Supply Chain
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
1,044
Wert ($)
0
#Aktien Gesamt
4,647
BARRY JAMESSep 06 '26
EVP, President, LSG
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
1,056
Wert ($)
0
#Aktien Gesamt
2,495
EVRAN SEDATSep 06 '26
EVP, Global Supply Chain
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
864
Wert ($)
0
#Aktien Gesamt
3,880
Lakkaraju Roop KalyanSep 06 '26
EVP, Chief Financial Officer
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
1,536
Wert ($)
0
#Aktien Gesamt
4,933
Allison SchwartzSep 06 '26
Director
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
92
Wert ($)
0
#Aktien Gesamt
1,768
SCHWARTZ NORMAN DSep 06 '26
Chairman & CEO
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
3,455
Wert ($)
0
#Aktien Gesamt
450,873
ENGELHARDT EVA ANETTESep 06 '26
EVP, President, CDG
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
1,152
Wert ($)
0
#Aktien Gesamt
2,313
ENLOE COURTNEY CSep 06 '26
EVP, General Counsel & Sec
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
768
Wert ($)
0
#Aktien Gesamt
1,957
SCHWARTZ NORMAN DSep 05 '26
Chairman & CEO
Transaktion
Option Exercise
Kosten
$0.00
#Aktien
4,109
Wert ($)
0
#Aktien Gesamt
450,294

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	#Aktien Gesamt
DiVincenzo Jonathan P.	President & COO	Oct 24 '26	Option Exercise	$0.00	1,869	3,832
EVRAN SEDAT	EVP, Global Supply Chain	Oct 20 '26	Option Exercise	$0.00	1,044	4,647
BARRY JAMES	EVP, President, LSG	Sep 06 '26	Option Exercise	$0.00	1,056	2,495
EVRAN SEDAT	EVP, Global Supply Chain	Sep 06 '26	Option Exercise	$0.00	864	3,880
Lakkaraju Roop Kalyan	EVP, Chief Financial Officer	Sep 06 '26	Option Exercise	$0.00	1,536	4,933
Allison Schwartz	Director	Sep 06 '26	Option Exercise	$0.00	92	1,768
SCHWARTZ NORMAN D	Chairman & CEO	Sep 06 '26	Option Exercise	$0.00	3,455	450,873
ENGELHARDT EVA ANETTE	EVP, President, CDG	Sep 06 '26	Option Exercise	$0.00	1,152	2,313
ENLOE COURTNEY C	EVP, General Counsel & Sec	Sep 06 '26	Option Exercise	$0.00	768	1,957
SCHWARTZ NORMAN D	Chairman & CEO	Sep 05 '26	Option Exercise	$0.00	4,109	450,294

Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten

Oct 31, 2026

Avoiding Lag: Real-Time Signals in (BIO) Movement - Stock Traders Daily

Oct 31, 2026

Oct 30, 2026

BIO.B SEC Filings, May-Sep 2026 - BIO-RAD LABORATORIES, INC. Filing Archive - Stock Titan

Oct 30, 2026

Oct 29, 2026

Bio-Rad Laboratories, Inc. Class B (BIO.B) Q3 2025 Earnings Report - Results, Call & Slides - TipRanks

Oct 29, 2026

Oct 28, 2026

Bio-Rad Laboratories, Inc. Class B (BIO.B) Q1 2026 Earnings Report - Results, Call & Slides - TipRanks

Oct 28, 2026

Bio-Rad Laboratories (BIO) Advances on Restructuring Plans and Margin Improvement Potential, Ariel Appreciation Fund Says - Yahoo Finance

Oct 28, 2026

Oct 27, 2026

Form 4 BIO-RAD LABORATORIES: Jonathan P. DiVincenzo (President & COO) For: 24 October - Investing.com UK

Oct 27, 2026

With awards vesting 25% yearly, Bio-Rad (BIO) COO acquires 1,869 shares. - Stock Titan

Oct 27, 2026

BIO (BIO) vs. TMO and DHR: Can Activist Pressure Close Bio-Rad’s Valuation Discount? - Yahoo Finance

Oct 27, 2026

Oct 22, 2026

Form 4 BIO-RAD LABORATORIES: Sedat Evran (EVP, Global Supply Chain) For: 20 October By Investing.com - Investing.com South Africa

Oct 22, 2026

Sedat Evran Reports Vesting of 1,044 Bio-Rad RSUs with Tax Share Disposal on October 20, 2026 - Kalkine Media

Oct 22, 2026

Oct 21, 2026

Bio-Rad Laboratories, Inc. Class B (BIO.B) Earnings Dates, Call Summary & Reports - TipRanks

Oct 21, 2026

Oct 20, 2026

Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026 - Investing News Network

Oct 14, 2026

Oct 10, 2026

Liquidity Mapping Around (BIO) Price Events - Stock Traders Daily

Oct 10, 2026

Oct 06, 2026

Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates - Zacks Investment Research

Oct 06, 2026

Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.

Oct 06, 2026

Bio-Rad Reports Second-Quarter 2026 Financial Results - Investing News Network

Oct 06, 2026

Oct 05, 2026

Europe Point of Care Diagnostics Market Size and Forecast, 2021 - 2031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.

Oct 05, 2026

Immunogenomics Market Size, Share, Trends, and Growth Forecast, 2026-2033 | NGS and Personalized Medicine Drive Market Toward USD 9.82 Billion at 5.97% CAGR - GlobeNewswire Inc.

Oct 05, 2026

Magnetic Beads Market - Global Forecast and Growth Opportunities, 2026-2032 | Automation, Genomics, and Molecular Diagnostics Drive 7.91% CAGR Toward USD 6.18 Billion - GlobeNewswire Inc.

Oct 05, 2026

Sep 30, 2026